Clinical trial · no report yet · Phase 4
CHECKMATE 920
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
- NCT02982954 ↗
- Completed
- Bristol-Myers Squibb
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| Podcasts | 2 | |
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)
- Phase
- Phase 4
- Status
- Completed
- Conditions
- Renal Cell Carcinoma
- Interventions
- Nivolumab; Ipilimumab
- Arms
- ccRCC KPS ≥ 70% · Experimental
- Non-ccRCC, KPS ≥ 70% · Experimental
- RCC with non-active Brain Mets, KPS ≥70% · Experimental
- any RCC with KPS 50%-60% · Experimental
- Enrollment
- 211
- Primary outcomes
- Number of Participants With High Grade (Grade 3-4) Immune Mediated Adverse Events (IMAEs)
- Number of Participants With High Grade (Grade 5) Immune Mediated Adverse Events (IMAEs)
- Sponsor
- Bristol-Myers Squibb
- Start
- Jan 16, 2017
- Primary completion
- May 11, 2020
- Results posted
- Yes
- Registry record
- NCT02982954 · updated Nov 1, 2022
Publications
linked from the registry- George DJ, Spigel DR, Gordan LN, Kochuparambil ST, Molina AM, Yorio J, Rezazadeh Kalebasty A, McKean H, Tchekmedyian N, Tykodi SS, Zhang J, Askelson M, Johansen JL, Hutson TE. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. BMJ Open. 2022 Sep 14;12(9):e058396. doi: 10.1136/bmjopen-2021-058396. PubMed 36104138
- Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, Singal R, Van Veldhuizen P, George DJ, Hutson T, Zhang J, Zoco J, Johansen JL, Rezazadeh Kalebasty A. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer. 2022 Feb;10(2):e003844. doi: 10.1136/jitc-2021-003844. PubMed 35210307